Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KAT7 | O95251 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.33 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840050 | 1.00 | PARP1 (0.37) | PARP1NR1H2MEN1KMT2AMAPT | |
| SCHEMBL4843374 | 0.93 | PARP1 (0.36) | PARP1NR1H2MEN1KMT2AMAPT | |
| SCHEMBL29318680 | 0.83 | MEN1 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL29551042 | 0.82 | PDE8B (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4406008 | 0.82 | PDE8B (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL29550324 | 0.82 | PDE8B (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6730924 | 0.81 | NR1H2 (0.36) | NR1H2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6730928 | 0.81 | NR1H2 (0.36) | NR1H2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL25757548 | 0.80 | NR1H2 (0.43) | NR1H2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL15373107 | 0.80 | NR1H2 (0.46) | NR1H2MEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | PARP1 2330/4885NR1H2 498/4885MEN1 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.